Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

[1]  Bibiana Bielekova,et al.  Daclizumab Therapy for Multiple Sclerosis , 2012, Neurotherapeutics.

[2]  T. Waldmann,et al.  A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy , 2011, Nature Medicine.

[3]  T. Waldmann,et al.  CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. , 2011, Blood.

[4]  T. Waldmann,et al.  Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. , 2010, Blood.

[5]  Yun Zhang,et al.  The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[6]  A. Bazarbachi,et al.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Kandaswamy,et al.  Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. , 2010, Transplantation proceedings.

[8]  Xavier Montalban,et al.  Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta , 2010, The Lancet Neurology.

[9]  A. Webster,et al.  Interleukin 2 receptor antagonists for kidney transplant recipients. , 2010, The Cochrane database of systematic reviews.

[10]  M. Sarwal,et al.  Extended daclizumab monotherapy for rejection‐free survival in non‐adherent adolescent recipients of renal allografts , 2009, Pediatric transplantation.

[11]  H. Tedesco-Silva,et al.  The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study , 2009, Transplantation.

[12]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Waldmann,et al.  Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. , 2008, Blood.

[14]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[15]  R. Ueda,et al.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Horwitz,et al.  A Multicenter Clinicopathologic Experience of HTLV-1 ATLL: A Retrospective 15 Year Review Reveals Little Progress. , 2007 .

[17]  E. Benedetti,et al.  Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL‐2 receptor blockade in an islet transplant recipient , 2007, Clinical transplantation.

[18]  T. Waldmann,et al.  Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Waldmann,et al.  Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. , 2006, Leukemia research.

[20]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Minnie M Sarwal,et al.  Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation1 , 2003, Transplantation.

[22]  C. Tei,et al.  Autocrine and/or paracrine growth of adult T‐cell leukaemia tumour cells by interleukin 15 , 2002, British journal of haematology.

[23]  T. Waldmann,et al.  IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Waldmann,et al.  IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. , 2000, Cancer research.

[25]  J. D. White,et al.  Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Waldmann,et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Nashan,et al.  Reduction of acute allograft rejection by daclizumab , 1999 .

[28]  J. Carrasquillo,et al.  Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Pescovitz,et al.  Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation , 1998 .

[30]  T. Waldmann,et al.  Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. , 1995, Blood.

[31]  T. Waldmann,et al.  The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia , 1993 .

[32]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[33]  P. Familletti,et al.  Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. , 1991, Journal of immunology.

[34]  W. P. Schneider,et al.  Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. , 1990, Cancer research.

[35]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[37]  W. Blattner,et al.  Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. , 1984, The Journal of clinical investigation.

[38]  T. Waldmann,et al.  NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. , 1984, Annals of internal medicine.

[39]  M. Reitz,et al.  Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Yoshida,et al.  Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Yodoi,et al.  Adult T-cell leukemia: clinical and hematologic features of 16 cases. , 1977, Blood.

[42]  H. Mano,et al.  Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. , 2008, International journal of oncology.

[43]  Malcolm S. Ke,et al.  Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). , 2002, Archives of dermatology.

[44]  D. Nelson,et al.  A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. , 1985, Hybridoma.

[45]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .